Advertisement


Dung T. Le, MD, on Noncolorectal GI Cancers: Results From a Phase II Study of Pembrolizumab

2016 Gastrointestinal Cancers Symposium

Advertisement

Dung T. Le, MD, from Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, reports findings on this agent, which showed promising activity in patients with previously treated progressive, advanced cancer (Abstract 195).



Related Videos

Colorectal Cancer

Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial (French Language Version)

Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses in French the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract ...

Gastroesophageal Cancer

Somnath Mukherjee, MD, on Esophageal Adenocarcinoma: Results of the NEOSCOPE Trial

Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based ch...

Colorectal Cancer

Eric Francois, MD, on Rectal Cancer: Findings From the ACCORD12 Trial

Eric Francois, MD, of the Centre Antoine-Lacassagne, discusses the 5-year follow-up results from this phase III study of neoadjuvant treatment in rectal cancer (Abstract 490). To v...

Gastroesophageal Cancer

Toshihiko Doi, MD, PhD, on Esophageal Carcinoma: Study Results From KEYNOTE-028

Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).

Gastroesophageal Cancer

Simron Singh, MD, on Neuroendocrine Tumors of the GI Tract: Results from the RADIANT-4 Trial

Simron Singh, MD, of the Toronto Sunnybrook Cancer Centre, discusses an analysis of data from this phase III study on the efficacy and safety of everolimus in advanced, progressive...

Advertisement

Advertisement



Advertisement